Search Results 531-540 of 16907 for Celecoxib

1. Targeted Drug Therapy Clinical Trials - Mayo Clinic Research

   Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does ...

2. Ethinyl estradiol and etonogestrel (vaginal route) - Side effects & dosage - Mayo Clinic

   Etonogestrel and ethinyl estradiol combination is used to prevent pregnancy. It is a flexible birth control vaginal ring that contains two types of hormones, ...

3. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma - Mayo Clinic

   Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

4. Selumetinib (oral route) - Mayo Clinic

   This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Capsule. Back to top ...

5. Clinical trials - Oncology (Medical)

   Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

6. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   About this study. The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active ...

7. Clinical trials - Oncology (Medical)

   This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and ...

8. A Study of Using Palbociclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive/ Human Epidermal Growth Factor Receptor 2 Negative Early Breast Cancer - Mayo Clinic

   The purpose of this study is to evaluate the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early ...

9. Clinical trials - Oncology (Medical)

   The purpose of this study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive ...

10. https://www.mayoclinic.org/spanish_organization_concepts.xml